Ray Taylor

A direct-acting antiviral drug abrogates viremia in Zika virus–infected rhesus macaques

Dane R. Schalk, A. Perelson, K. Best, 2020, Science Translational Medicine.

Galidesivir limits Rift Valley fever virus infection and disease in Syrian golden hamsters

B. Gowen, Brady T. Hickerson, J. Westover, 2018, Antiviral Research.

Activity of Galidesivir in a Hamster Model of SARS-CoV-2

H. Bielefeldt-Ohmann, R. Bowen, Airn E. Hartwig, 2021, Viruses.

An update on the progress of galidesivir (BCX4430), a broad-spectrum antiviral

B. Gowen, D. Walling, A. Mathis, 2021, Antiviral Research.

Efficacy of the broad‐spectrum antiviral compound BCX4430 against Zika virus in cell culture and in a mouse model

W. Sheridan, A. V. Wettere, A. V. Van Wettere, 2017, Antiviral research.

BCX4430 – A broad-spectrum antiviral adenosine nucleoside analog under development for the treatment of Ebola virus disease

S. Bavari, R. Panchal, W. Sheridan, 2016, Journal of Infection and Public Health.

BCX4430 – A broad-spectrum antiviral adenosine nucleoside analog under development for the treatment of Ebola virus disease

S. Bavari, R. Panchal, W. Sheridan, 2016, Journal of Infection and Public Health.

Pharmacokinetics and Safety of the Nucleoside Analog Antiviral Drug Galidesivir Administered to Healthy Adult Subjects

W. Sheridan, D. Walling, Ray Taylor, 2022, Clinical pharmacology in drug development.